Analysts forecast that Omnicell, Inc. (NASDAQ:OMCL) will post earnings per share (EPS) of $0.41 for the current quarter, Zacks reports. Three analysts have made estimates for Omnicell’s earnings. The lowest EPS estimate is $0.40 and the highest is $0.43. Omnicell posted earnings per share of $0.40 during the same quarter last year, which would indicate a positive year over year growth rate of 2.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, October 26th.

On average, analysts expect that Omnicell will report full-year earnings of $1.29 per share for the current financial year, with EPS estimates ranging from $1.28 to $1.32. For the next financial year, analysts forecast that the business will report earnings of $2.04 per share, with EPS estimates ranging from $2.00 to $2.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Omnicell.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 earnings per share.

Several analysts recently weighed in on the company. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and set a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Craig Hallum lifted their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Dougherty & Co lifted their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.57.

TRADEMARK VIOLATION WARNING: “$0.41 EPS Expected for Omnicell, Inc. (OMCL) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/05/0-41-eps-expected-for-omnicell-inc-omcl-this-quarter.html.

Omnicell (OMCL) traded up 0.29% during mid-day trading on Thursday, hitting $52.50. The stock had a trading volume of 336,440 shares. The firm’s market capitalization is $1.97 billion. The stock’s 50 day moving average price is $49.97 and its 200 day moving average price is $44.59. Omnicell has a one year low of $30.35 and a one year high of $52.70.

In other news, Chairman Randall A. Lipps sold 37,500 shares of Omnicell stock in a transaction on Friday, July 28th. The stock was sold at an average price of $46.00, for a total value of $1,725,000.00. Following the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $9,041,346. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 40,000 shares of Omnicell stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $9,780,377.76. The disclosure for this sale can be found here. Insiders sold a total of 184,094 shares of company stock valued at $9,094,791 over the last ninety days. Insiders own 3.77% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in Omnicell during the 1st quarter worth $125,000. Oppenheimer Asset Management Inc. bought a new stake in Omnicell during the 1st quarter worth $170,000. Turner Investments LLC bought a new stake in Omnicell during the 2nd quarter worth $181,000. Riverhead Capital Management LLC grew its position in Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after acquiring an additional 1,830 shares during the last quarter. Finally, Flinton Capital Management LLC grew its position in Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after acquiring an additional 1,802 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.